TGFbetaRIIDN-armored anti-ROR1 CAR T-cell therapy (Lentigen Technology)

N/A

Report date: 2025/06/11 10:39:45

Base Information

Drug NameTGFbetaRIIDN-armored anti-ROR1 CAR T-cell therapy (Lentigen Technology)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 modulatorsT lymphocytes stimulantsImmunostimulants +[4]

TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1Transforming growth factor beta

Therapy Area/IndicationsSolid tumoursPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLentigen Technology Inc

China Registration ClassN/A

Develop Information

Active CompaniesLentigen Technology Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A